title: Bone Metastases and the EGFR and KRAS Mutation Status in Lung Adenocarcinoma--The Results of Three Year Retrospective Analysis.
abstract: Lung cancer is a heterogeneous group of disease and mutational profiling of lung adenocarcinomas is a routine practice in thoracic oncology. Kirsten-RAS (KRAS) and EGFR mutations play an important role in the carcinogenesis of a subset of lung adenocarcinomas. Our aim was to investigate the correlation between bone metastases and EGFR and KRAS mutation status in lung adenocarcinoma patients. Retrospectively we analysed 224 patients with recurrent or metastatic lung adenocarcinomas. Patients were treated with standard chemotherapy as first line therapy and with EGFR-TK inhibitors as a second or third line therapy. 72 of 224 patients (32 %) had verified bone metastases. Bone metastases and Skeletal Related Events (SRE) were more frequent in men, heavy smokers and without treatment of EGFR TK inhibitors. We have found that EGFR and KRAS mutation status are both predictive factors for the treatment efficacy and prognostic factors for the disease progression. However there were no significant correlation between mutation status and the presence of bone metastases (P = 0, 59). In our study the presence of bone metastases proved to be an independent prognostic factor related to poor performance status and worse Quality of Life (QL).
authors.affiliation: National Institute of Oncology, Budapest, Hungary, nora_bittner@yahoo.ca.
authors.forename: Nóra
authors.initials: N
authors.lastname: Bittner
authors.forename: Zoltán
authors.initials: Z
authors.lastname: Balikó
authors.forename: Veronika
authors.initials: V
authors.lastname: Sárosi
authors.forename: Terézia
authors.initials: T
authors.lastname: László
authors.forename: Erika
authors.initials: E
authors.lastname: Tóth
authors.forename: Miklós
authors.initials: M
authors.lastname: Kásler
authors.forename: Lajos
authors.initials: L
authors.lastname: Géczi
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy / Q000235:genetics* / Q000473:pathology; D000077192:Adenocarcinoma of Lung; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001859:Bone Neoplasms / Q000235:genetics* / Q000473:pathology / Q000556:secondary; D018450:Disease Progression; D066246:ErbB Receptors / Q000235:genetics*; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy / Q000235:genetics* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009154:Mutation / Q000235:genetics*; D011379:Prognosis; D016283:Proto-Oncogene Proteins p21(ras) / Q000235:genetics*; D011788:Quality of Life; D012189:Retrospective Studies
chemical_list: D000970:Antineoplastic Agents; C117307:KRAS protein, human; C512478:EGFR protein, human; D066246:ErbB Receptors; D016283:Proto-Oncogene Proteins p21(ras)